Minerva Neurosciences, Inc. Investment Income, Amortization of Premium
Minerva Neurosciences, Inc. (NERV) reported Investment Income, Amortization of Premium of $102.63 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-13.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeAmortizationOfPremium · last filed 2017-03-13
- Minerva Neurosciences, Inc. investment income, amortization of premium for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- Minerva Neurosciences, Inc. investment income, amortization of premium for the quarter ending 2016-09-30 was $11.90K, a 87.04% decline year-over-year.
- Minerva Neurosciences, Inc. investment income, amortization of premium for the quarter ending 2016-06-30 was $30.91K.
- Minerva Neurosciences, Inc. investment income, amortization of premium for the quarter ending 2016-03-31 was $59.82K.
- Minerva Neurosciences, Inc. investment income, amortization of premium for fiscal 2016 was $102.63K, a 58.49% decline from fiscal 2015.
- Minerva Neurosciences, Inc. investment income, amortization of premium for fiscal 2015 was $247.26K.
| Period end | Investment Income, Amortization of Premium 3 month | Investment Income, Amortization of Premium 6 month | Investment Income, Amortization of Premium 9 month | Investment Income, Amortization of Premium 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $11.90K derived: sum of 2 quarters · filed 2017-03-13 | $42.81K derived: sum of 3 quarters · filed 2017-03-13 | $102.63K 10-K · filed 2017-03-13 |
| 2016-09-30 | $11.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $42.81K derived: sum of 2 quarters · filed 2016-11-03 | $102.63K 10-Q · filed 2016-11-03 | $190.21K derived: sum of 4 quarters · filed 2017-03-13 |
| 2016-06-30 | $30.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $90.73K 10-Q · filed 2016-08-04 | $178.32K derived: sum of 3 quarters · filed 2017-03-13 | $270.15K derived: sum of 4 quarters · filed 2017-03-13 |
| 2016-03-31 | $59.82K 10-Q · filed 2016-05-03 | $147.40K derived: sum of 2 quarters · filed 2017-03-13 | $239.23K derived: sum of 3 quarters · filed 2017-03-13 | |
| 2015-12-31 | $87.58K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $179.41K derived: sum of 2 quarters · filed 2017-03-13 | $247.26K 10-K · filed 2017-03-13 | |
| 2015-09-30 | $91.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $159.68K 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | $67.85K 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |